NCT07127315Completed
Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy
Concurrent Goserelin During Chemotherapy for Ovarian Function Preservation in Premenopausal Breast Cancer: An Open-Label Randomized Trial
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to investigate the benefits of gonadotropin-releasing hormone agonist administration during chemotherapy on preserving ovarian function and Fertility in Premenopausal breast cancer patients, as assessed by anti-mullerian hormone levels, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E2) levels.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 10 Aug 2025
- Start date
- Jun 2022
- Primary completion date
- Jul 2024
- Lead sponsor
- Helwan University
- Diseases
- Ovarian cancer
- NCT number
- NCT07127315
What you commit to
- Study type: Interventional
- Participants enrolled: 100
- From Jun 2022 to the primary completion date, Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy, or patients received radiotherapy on the pelvis.
Other illness
- All female Patients with metastatic cancer.
- Patient with end-organ failure.
- Male with breast cancer.
Other
- Patients with performance status \>2.
- Post-menopausal females.
Who the study is looking for
- Premenopausal female patients 18-45 years.
- Female patients with pathologically confirmed breast cancer and receiving a chemotherapy regimen, either adjuvant or neoadjuvant, containing a gonadotoxic agent.
- Female patients with performance status (PS) ≤ 2.
Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Helwan University Coordinator of this site? Confirm its status | Helwan | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.